Results 31 to 40 of about 4,608 (197)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements

Cancers, 2023
Neuroendocrine neoplasms (NENs) are tumors originating from neuroendocrine cells distributed throughout the human body. With an increasing incidence over the past few decades, they represent a highly heterogeneous group of neoplasms, mostly expressing somatostatin receptors (SSTRs) on their cell surface. Peptide receptor radionuclide therapy (PRRT) has
Elettra Merola, Chiara Maria Grana
openaire   +3 more sources

Long-Term Survival and Value of ¹⁸F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with ¹⁷⁷Lu-DOTATATE

Life, 2021
Peptide receptor radionuclide therapy (PRRT) has been recognized as a promising therapy against neuroendocrine tumors (NETs). The use of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in NETs has been a matter of controversy.
Margarida Rodrigues, Kevin-Klaus Winkler, Hanna Svirydenka, Bernhard Nilica, Christian Uprimny, Irene Virgolini   +5 more
doaj   +1 more source

177Lu-DOTATATE therapy in metastatic/ inoperable pheochromocytoma-paraganglioma

Endocrine Connections, 2020
Introduction: 177Lu-DOTATATE-based peptide receptor radionuclide therapy (PRRT) is a promising therapy for metastatic and/or inoperable pheochromocytoma and paraganglioma (PPGL).
Sanjeet Kumar Jaiswal, Vijaya Sarathi, Saba Samad Memon, Robin Garg, Gaurav Malhotra, Priyanka Verma, Ravikumar Shah, Manjeet Kaur Sehemby, Virendra A Patil, Swati Jadhav, Anurag Ranjan Lila, Nalini S Shah, Tushar R Bandgar   +12 more
doaj   +1 more source

Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: A systematic review

Frontiers in Endocrinology, 2022
PurposeTargeted radionuclide therapy (TRT) with [131I]MIBG and [177Lu]Lu-DOTA-TATE is an alternative treatment to the classic schemes in slow progressive metastatic/inoperable paraganglioma (PGL) and pheochromocytoma (PHEO).
Stefan Prado-Wohlwend, María Isabel del Olmo-García, Pilar Bello-Arques, Juan Francisco Merino-Torres, Juan Francisco Merino-Torres   +4 more
doaj   +1 more source

PRRT: An Intelligent Planning Algorithm with Memory

Journal of Physics: Conference Series, 2022
Abstract This paper proposes a practically executable path planning method, namely, Pheromones-RRT(PRRT), for robots with a large joint range in a complex environment. To inter-activate with the real world, the point cloud is utilized as the scene information, while for sampling, the pheromones approach is designed to describe the ...
Qinhu Chen, Meilin Kang, Zeming Fan, Xiaojun Yu   +3 more
openaire   +1 more source

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor

Diagnostics, 2013
Peptide receptor radionuclide therapy (PRRT) is a relatively new mode of internally targeted radiotherapy currently in clinical trials. In PRRT, ionizing radioisotopes conjugated to somatostatin analogues are targeted to neuroendocrine tumors (NETs) via ...
Michael Bzorek, Michael Holmsgaard Kristensen, Andreas Kjaer, Andreas Klaus Pfeifer, Ulrich Knigge, Yin Wu, Rajendra Singh Garbyal, Palle Rasmussen, Rebecca Myschetzky   +8 more
doaj   +1 more source

Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy

Frontiers in Endocrinology
BackgroundPeptide receptor radionuclide therapy (PRRT) is a well-established treatment option for neuroendocrine tumors (NET), yet randomized controlled trials have not provided data on its impact on overall survival.
Annie Mathew, David Kersting, Wolfgang P. Fendler, Johanna Braegelmann, Dagmar Fuhrer, Harald Lahner   +5 more
doaj   +1 more source

A Partially Multiplexed HIV Drug Resistance (HIVDR) Assay for Monitoring HIVDR Mutations of the Protease, Reverse-Transcriptase (PRRT), and Integrase (INT)

Microbiology Spectrum, 2022
As dolutegravir (DTG)-containing HIV regimens are scaled up globally, monitoring for HIV drug resistance (HIVDR) will become increasingly important.
Joshua DeVos, Kimberly McCarthy, Victor Sewe, Grace Akinyi, Muthoni Junghae, Valarie Opollo, Janin Nouhin, Robert Shafer, Clement Zeh, Artur Ramos, Heather Alexander, Joy Chang   +11 more
doaj   +1 more source

Long-term prognostic factors for PRRT in neuroendocrine tumors

Frontiers in Medicine, 2023
Aim/introductionPeptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment option for patients with neuroendocrine tumors (NETs) that prolongs progression-free survival (PFS). However, the limited overall survival (OS) rates in the prospective phase III study (NETTER1) highlighted the need to identify patient-specific ...
Nils Florian Trautwein, Nils Florian Trautwein, Nils Florian Trautwein, Johannes Schwenck, Johannes Schwenck, Johannes Schwenck, Johann Jacoby, Gerald Reischl, Gerald Reischl, Francesco Fiz, Francesco Fiz, Lars Zender, Lars Zender, Lars Zender, Lars Zender, Helmut Dittmann, Helmut Dittmann, Martina Hinterleitner, Martina Hinterleitner, Martina Hinterleitner, Christian la Fougère, Christian la Fougère, Christian la Fougère, Christian la Fougère   +23 more
openaire   +3 more sources

Case Report: PRRT in a patient with Zollinger-Ellison syndrome. The management of gastrointestinal complications

Frontiers in Oncology
Zollinger-Ellison Syndrome (ZES) is a rare condition characterized by excessive gastric acid secretion due to gastrin-producing neuroendocrine tumors.
Martina Di Franco, Rexhep Durmo, Maria Liberata Di Paolo, Roberto Giacosa, Elisa Bannò, Valentina Ambrosini, Valentina Ambrosini, Angelina Filice   +7 more
doaj   +1 more source